Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2025-12-27 @ 7:06 AM
Study NCT ID:
NCT04142060
Status:
TERMINATED
Last Update Posted:
2022-10-28
First Post:
2019-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
Sponsor:
SOLTI Breast Cancer Research Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-06-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-10
Completion Date Type:
ACTUAL
First Submit Date:
2019-10-25
First Submit QC Date:
None
Study First Post Date:
2019-10-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-25
Last Update Post Date:
2022-10-28
Last Update Post Date Type:
ACTUAL